Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
& McCoy, K
CrossRef Non-alcoholic fatty liver disease and Helicobacter pylori infection: problems and solutions
Structure Therapeutics and Pfizer are developing absorption-enhancer-free or twice-daily oral candidates aiming to expand convenience
doi: 10.3389/fphar.2025.1735760 Received 30 October 2025 Revised 14 December 2025 Accepted 19 December 2025 Published 27 February 2026 Volume 16 - 2025 Edited by Vigyasa Singh, University of Arizona, United States Reviewed by Mayasah Al-Nema, University of British Columbia, Canada Rituraj Purohit, Institute of Himalayan Bioresource Technology (CSIR), India Chiara Brullo, University of Genoa, Italy Updates Copyright 2026 Rautela, Gaurav, Nissapatorn, Tan, Girol, Pereira and Lee
US$ 29.67
US$ 22.97
US$ 29.26
US$ 22.96
US$ 26.65
US$ 22.02
US$ 28.39
US$ 25.10
